120 related articles for article (PubMed ID: 37405857)
1. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Pesántez D; Ten Hoorn S; Machado I; García-Albéniz X; Rodríguez-Salas N; Heredia-Soto V; Viñal D; Pericay C; García-Carbonero R; Losa F; Alonso V; Vera R; Feliu Batlle J; Gallego J; Salud A; Nogué M; Layos L; Montagut C; Capdevila J; Vermeulen L; Maurel J; Fernandez-Martos C
J Natl Cancer Inst; 2023 Dec; 115(12):1497-1505. PubMed ID: 37405857
[TBL] [Abstract][Full Text] [Related]
2. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
Fernández-Martos C; Pericay C; Losa F; García-Carbonero R; Layos L; Rodríguez-Salas N; Martin-Richard M; Alonso-Orduña V; Vera R; Gallego J; Capdevila J; Salud A; Nogué M; Maurel J; Guash I; Montagut C; Lopez C; Macias I; Jain RK; Garcia-Albeniz X
JAMA Oncol; 2019 Nov; 5(11):1566-1573. PubMed ID: 31465088
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
4. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.
Jimenez-Rodriguez RM; Quezada-Diaz F; Hameed I; Kalabin A; Patil S; Smith JJ; Garcia-Aguilar J
Dis Colon Rectum; 2021 Dec; 64(12):1463-1470. PubMed ID: 34508014
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Wu X; Peng J; Ren D; Wang J
J Clin Oncol; 2019 Dec; 37(34):3223-3233. PubMed ID: 31557064
[TBL] [Abstract][Full Text] [Related]
6. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Peng J; Ren D; Wang J
J Clin Oncol; 2016 Sep; 34(27):3300-7. PubMed ID: 27480145
[TBL] [Abstract][Full Text] [Related]
7. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
8. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.
Fernandez-Martos C; Garcia-Albeniz X; Pericay C; Maurel J; Aparicio J; Montagut C; Safont MJ; Salud A; Vera R; Massuti B; Escudero P; Alonso V; Bosch C; Martin M; Minsky BD
Ann Oncol; 2015 Aug; 26(8):1722-8. PubMed ID: 25957330
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
13. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
[TBL] [Abstract][Full Text] [Related]
14. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
Jin J; Tang Y; Hu C; Jiang LM; Jiang J; Li N; Liu WY; Chen SL; Li S; Lu NN; Cai Y; Li YH; Zhu Y; Cheng GH; Zhang HY; Wang X; Zhu SY; Wang J; Li GF; Yang JL; Zhang K; Chi Y; Yang L; Zhou HT; Zhou AP; Zou SM; Fang H; Wang SL; Zhang HZ; Wang XS; Wei LC; Wang WL; Liu SX; Gao YH; Li YX
J Clin Oncol; 2022 May; 40(15):1681-1692. PubMed ID: 35263150
[TBL] [Abstract][Full Text] [Related]
17. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
18. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
[TBL] [Abstract][Full Text] [Related]
20. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.
Marco MR; Zhou L; Patil S; Marcet JE; Varma MG; Oommen S; Cataldo PA; Hunt SR; Kumar A; Herzig DO; Fichera A; Polite BN; Hyman NH; Ternent CA; Stamos MJ; Pigazzi A; Dietz D; Yakunina Y; Pelossof R; Garcia-Aguilar J;
Dis Colon Rectum; 2018 Oct; 61(10):1146-1155. PubMed ID: 30192323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
